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ABSTRACT
Objective To improve the echocardiographic 
assessment of heart failure in patients with atrial 
fibrillation (AF) by comparing conventional averaging of 
consecutive beats with an index- beat approach, whereby 
measurements are taken after two cycles with similar R- R 
interval.
Methods Transthoracic echocardiography was 
performed using a standardised and blinded protocol in 
patients enrolled in the RATE- AF (RAte control Therapy 
Evaluation in permanent Atrial Fibrillation) randomised 
trial. We compared reproducibility of the index- beat 
and conventional consecutive- beat methods to 
calculate left ventricular ejection fraction (LVEF), global 
longitudinal strain (GLS) and E/e’ (mitral E wave max/
average diastolic tissue Doppler velocity), and assessed 
intraoperator/interoperator variability, time efficiency and 
validity against natriuretic peptides.
Results 160 patients were included, 46% of whom 
were women, with a median age of 75 years (IQR 
69–82) and a median heart rate of 100 beats per minute 
(IQR 86–112). The index- beat had the lowest within- 
beat coefficient of variation for LVEF (32%, vs 51% 
for 5 consecutive beats and 53% for 10 consecutive 
beats), GLS (26%, vs 43% and 42%) and E/e’ (25%, vs 
41% and 41%). Intraoperator (n=50) and interoperator 
(n=18) reproducibility were both superior for index- beats 
and this method was quicker to perform (p<0.001): 35.4 
s to measure E/e’ (95% CI 33.1 to 37.8) compared with 
44.7 s for 5- beat (95% CI 41.8 to 47.5) and 98.1 s for 
10- beat (95% CI 91.7 to 104.4) analyses. Using a single 
index- beat did not compromise the association of LVEF, 
GLS or E/e’ with natriuretic peptide levels.
Conclusions Compared with averaging of multiple 
beats in patients with AF, the index- beat approach 
improves reproducibility and saves time without a 
negative impact on validity, potentially improving the 
diagnosis and classification of heart failure in patients 
with AF.
INTRODUCTION
The prevalence of atrial fibrillation (AF) is 
climbing,1 and around 50% of patients with AF 
have or will develop heart failure.2 3 Assessment 
of systolic and diastolic ventricular function using 
echocardiography is essential for AF management, 
including stroke risk stratification, choice of rate and 
rhythm control therapy, and the identification of 
heart failure.4 However, assessment of systolic and 
diastolic function is challenging in AF due to vari-
able R- R intervals leading to beat- to- beat changes in 
left ventricular function. This may explain why the 
association of echocardiography parameters with 
adverse events is weaker in AF compared with sinus 
rhythm.5 In clinical practice, multiple beats are 
averaged despite a lack of any evidence base for this 
approach.6 Multiple beat acquisition and analysis is 
time- consuming and may not adequately compen-
sate for the variable stroke volume and filling time 
seen in AF.7 To correctly classify heart failure in 
the context of AF and manage it appropriately, it is 
crucial to have accurate and reproducible measure-
ments of systolic and diastolic function.8
The aim of this study was to systematically 
compare the reproducibility and efficiency of a 
more physiological approach to improve the assess-
ment of heart failure in patients with AF. The index- 
beat method takes into account time- dependent 
processes involved in contractility and relaxation.9 
We compared this approach with conventional 
averaging of 3 beats (clinical routine) and 5 beats 
and 10 beats (as recommended in guidelines), with 
complete blinding of observers. Unlike previous 
studies, there was no preselected exclusion of 
patients according to image quality.10 We hypoth-
esised that the index- beat method would be more 
reproducible and time- efficient, facilitating better 
management of patients with AF and heart failure.
METHODS
Patient population
Baseline echocardiograms were evaluated for all 
participants enrolled in the RATE- AF (RAte control 
Therapy Evaluation in permanent Atrial Fibril-
lation) randomised trial after obtaining written 
informed consent (NCT02391337). The trial 
received oversight from a trial steering committee 
and data monitoring committee with independent 
chairs. The rationale and methods for the RATE- AF 
trial have previously been published.11 In brief, 
outpatients aged 60 years or older with permanent 
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AF and symptoms of heart failure (New York Heart Association 
class II or above) were randomised to digoxin or beta- blockers 
for rate control of AF. Permanent AF was defined as a physician’s 
decision for rate control and no plans for antiarrhythmic drugs 
or interventional rhythm control. Patients were excluded if their 
heart rate was <60 beats per minute or had prior evidence of 
second- degree or third- degree heart block. Other exclusion 
criteria were minimised to enable generalisable ‘real- world’ 
results. There were no exclusion criteria related to known heart 
failure or according to left ventricular ejection fraction (LVEF), 
apart from those with decompensated heart failure in the last 
14 days, evidenced by the need for intravenous inotropes, vaso-
dilators or diuretics.11 The trial was publicly funded by the UK 
National Institute for Health Research and the main results have 
been published.10
Echocardiography protocol
AF was confirmed on 12- lead ECG. All patients then under-
went transthoracic echocardiography using Philips EPIQ 7 and 
X5-1 transducer, by an experienced echocardiographer accred-
ited with the British Society of Echocardiography. Patients were 
positioned in left lateral decubitus position and images were 
acquired during quiet respiration according to an echocardiog-
raphy protocol ratified prior to the trial commencing.
A minimum of 30- beat loops were obtained of the apical two- 
chamber, three- chamber and four- chamber views. All images 
were optimised to maximise frame rate while ensuring all left 
ventricular segments were visible. A minimum of 30 traces of 
tissue Doppler imaging (TDI)- derived lateral and septal e’ were 
obtained and mitral inflow using pulse wave Doppler acquired 
at a sweep speed of 50 mm/s. The recorded images were given a 
unique identification number and all patient- identifiable features 
(including trial number) were removed, blinding the operator to 
patient, trial and clinical details.
All measurements were analysed offline by the same oper-
ator a minimum of 3 months after the scan date. To minimise 
selection bias, there were no predefined exclusions made on the 
quality of imaging; however, if image quality was insufficient 
to accurately obtain measurements, these images were excluded 
from analysis. All analyses were performed on Philips Q- Station 
(V.3.5; Philips Healthcare, Andover, Massachusetts). For LVEF, 
Simpson’s biplane LVEF was measured from the apical four- 
chamber and two- chamber views. Longitudinal strain was taken 
from the apical two- chamber, three- chamber and four- chamber 
views and then averaged to generate overall global longitudinal 
strain (GLS). The mean frame rate for GLS acquisition was 
57 Hertz (SD 7.0). For E/e’, mitral valve peak E velocity was 
measured and then divided by the TDI- derived e’ (averaged from 
the lateral and septal walls).
Index-beat and conventional averaging method
The index- beat was identified as the cardiac cycle which 
followed a preceding and pre- preceding R- R interval of similar 
duration (within 60 ms of each other; figure 1). R- R intervals 
were measured using a calliper in the reporting software. The 
index- beats were selected consecutively from the beginning of 
each set of echocardiogram data to avoid selection bias. Conven-
tional analysis involved averaging of 3, 5 and 10 consecutive 
cardiac cycles from a 10- beat data set.
Intraoperator reproducibility
The same operator took a second set of 10 images to measure 
GLS and E/e’ (using the methods described above) with a single 
index- beat and an average of 3, 5 and 10 beats.
Interoperator reproducibility and time comparison
A second accredited operator obtained images in 18 randomly 
selected patients to measure GLS and E/e’ using a single index- 
beat and average of 3, 5 and 10 beats. The operator was 
blinded to the previously recorded measurements as well as 
all clinical details of each echocardiogram. The time taken to 
select and measure E/e’ using a single index- beat and guideline- 
recommended 5 and 10 consecutive beats was measured, with 
time commencing from the first visualisation of Doppler images.
Validity
All patients had N- terminal pro- B- type natriuretic peptide 
(NT- proBNP) measured on the same day as their echocardio-
gram using an Abbott Alinity platform. This was correlated with 
the parameters LVEF Simpson’s biplane, GLS and E/e’.
Patient and public involvement
A patient and public involvement team were involved in the 
design and conduct of this study and assisted with the plain 
English summary.
Statistical analysis
Summary results are presented as percentage, mean with SD, or 
median with IQR (displayed as 25th–75th quartiles). All echo-
cardiographic measurements were transformed to their natural 
log value. A multilevel mixed effects linear regression model 
(adjusting for the random effects of the patient) was used to 
calculate the intraclass correlation coefficient (ICC) and derive 
the SD (σ), with 95% CI for the within- beat variability. Post- hoc 
analysis indicated >90% assurance that the sample size was 
sufficient for ICC comparison.12 The coefficient of variation 
(CV) within three index- beats and within each set of consec-
utive beats (3, 5 and 10) was calculated using the following 
formula: √exp(SD2)−1×100; 95% CIs were calculated for each 
CV. For intraoperator and interoperator reproducibility, Bland 
and Altman analysis was used to obtain the mean bias and limits 
of agreement, and the ICC with 95% CI was calculated at the 
patient level for each measurement method using a multilevel 
mixed effects linear regression model (adjusting for the random 
effects of the patient and the time the measurement was taken). 
The statistical comparison of time taken was performed using 
a two- tailed t- test accounting for unequal variance. The asso-
ciation with NT- proBNP was compared using Spearman’s r 
and univariate linear regression analysis. The difference in 
correlation coefficient between measuring on an index- beat and 
Figure 1 Index- beat approach versus conventional averaging of 
consecutive beats. Left panel: pulse wave mitral inflow Doppler using 
the index- beat method, with similar preceding and pre- preceding R- R 
intervals indicated by the red arrows. Values are the R- R interval length 
of the preceding cardiac cycle. Right panel: 3, 5 and 10 consecutive 
beats. Values are the peak E velocity measurement in cm/s.
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averaging 3, 5 and 10 consecutive beats was calculated using the 
method of Meng et al.13 Statistical analysis was performed using 
Stata V.14.2. A two- tailed p value of 0.05 was considered statis-
tically significant.
RESULTS
One hundred and sixty patients were included, with a median 
age of 75 years (IQR 69–82), heart rate of 100 beats per minute 
at time of acquisition (86–112) and blood pressure of 134/84 
mm Hg (123/76–148/93) (see table 1). The median LVEF was 
59% (52–64), GLS −14% (−12 to −15) and E/e’ 9.4 (7.8–11.7); 
variables measured by consecutive beats are listed in online 
supplemental table 2. Image quality was insufficient for LVEF 
measurement in 18 patients (11.3%) and for GLS in 21 patients 
(13.1%), with strain assessment more challenging at higher heart 
rates. All patients had sufficient image quality to measure E/e’. 
Other echocardiogram parameters of interest are summarised in 
table 2. Online supplemental figure 1 depicts the flow diagram 
of the study population. A plain English summary of results is 
presented in online supplemental table 1.
Within-beat reproducibility
The index- beat approach had less variability compared with 
conventional consecutive beat averaging for all comparisons of 
CV for LVEF, GLS and E/e’ (figure 2 and table 3). In all cases, 
the difference between the index- beat method and the vari-
ability of 3, 5 and 10 consecutive beats was statistically signif-
icant with no overlap of 95% CIs. Similarly, the index- beat 
approach demonstrated higher ICC values for LVEF, GLS and 
E/e’ (figure 3 and table 3).
For LVEF, the index- beat approach had the smallest CV of 
32% (95% CI 31 to 34) and strongest ICC of 0.94 (0.93 to 
0.96), compared with 54% (52 to 57) and 0.71 (0.64 to 0.77) 
for 3 consecutive beats, 51% (50 to 53) and 0.76 (0.71 to 0.81) 
for 5 consecutive beats, and 53% (52 to 54) and 0.74 (0.69 to 
0.79) for 10 consecutive beats. The mean RR1 of the index- 
beat (pre- preceding R- R interval) was 552 ms and the mean RR2 
(preceding R- R interval) was 555 ms, with a mean RR1 to RR2 
ratio of 1.00.
For GLS, the index- beat approach had the smallest CV of 26% 
(95% CI 25 to 27) and strongest ICC of 0.88 (0.85 to 0.91), 
compared with 44% (42 to 46) and 0.81 (0.76 to 0.85) for 3 
consecutive beats, 43% (42 to 44) and 0.82 (0.77 to 0.85) for 5 
consecutive beats, and 42% (41 to 43) and 0.80 (0.75 to 0.84) 
for 10 consecutive beats. The mean RR1 of the index- beat was 
Table 1 Baseline demographics
Characteristics N=160
Age, median years (IQR) 75 (69–82)
Women, n (%) 74 (46)
Years in AF, mean years (SD) 3.8 (6)
Ethnicity: white British or Irish, n (%) 149 (93.1)
Ethnicity: black African, Caribbean or black British, n (%) 3 (1.9)
Ethnicity: Asian or Asian British, n (%) 8 (5.01)
Previous rhythm control, n (%) 23 (14)
Modified EHRA class 3 or 4, n (%) 77 (48)
Previous heart failure clinical diagnosis, n (%) 59 (37)
Signs of heart failure at randomisation, n (%) 84 (53)
NYHA class III or IV, n (%) 61 (38)
Previous myocardial infarction, n (%) 13 (8)
Previous stroke, n (%) 19 (12)
Previous TIA, n (%) 15 (9)
COPD, n (%) 29 (18)
Diabetes mellitus, n (%) 38 (24)
Heart rate, median bpm (IQR) 100 (86–112)
Systolic BP, median mm Hg (IQR) 134 (123–148)
Diastolic BP, median mm Hg (IQR) 84 (76–93)
Body mass index, median kg/m2 (IQR) 30 (26–34)
NT- proBNP, median pg/mL (IQR) 1057 (744–1522)
Estimated GFR, median mL/min (IQR) 67 (55–77)
Already receiving anticoagulant medication, n (%) 135 (84)
Antihypertensive medication, n (%) 116 (73)
Inhalers for airway disease, n (%) 40 (25)
AF, atrial fibrillation; BP, blood pressure; bpm, beats per minute; COPD, chronic 
obstructive pulmonary disorder; EHRA, European Heart Rhythm Association; GFR, 
glomerular filtration rate; NT- proBNP, N- terminal pro- B- type natriuretic peptide; 
NYHA, New York Heart Failure Association functional classification; TIA, transient 
ischaemic attack.
Table 2 Echocardiography parameters
Echocardiographic measurement Baseline
Left ventricular end diastolic volume, median mL (IQR) 76 (57–99)
Left ventricular end systolic volume, median mL (IQR) 30 (22–42)
Stroke volume, median mL (IQR) 55 (45–64)
Left ventricular ejection fraction, median % (IQR) 59 (52–64)
Global longitudinal strain, median % (IQR) −14 (−12 to −15)
Lateral s’, median cm/s (IQR) 6.7 (5.6–7.9)
Septal s’, median cm/s (IQR) 6.1 (5.1–7.2)
Average e’, median cm/s (IQR) 9.3 (8.1–10.9)
Mitral E velocity, median cm/s (IQR) 89.7 (77.1–102.8)
Mitral deceleration time, median ms (IQR) 212 (188–234)
Average E/e’, median (IQR) 9.4 (7.8–11.7)
Isovolumic relaxation time, median ms (IQR) 97 (89–108)
Pulmonary vein ratio, mean (SD) 0.7 (0.1)
Pulmonary vein deceleration time, median (IQR) 242 (223–258)
Left atrial volume indexed to BSA, median mL/m2 (IQR) 38 (32–49)
Left atrial ejection fraction, median % (IQR) 23 (15–33)
TAPSE mm, median (IQR) 18.7 (17.1–21.8)
BSA, body surface area; TAPSE, tricuspid annular plane systolic excursion.
Figure 2 Comparison of the coefficient of variation of within- beat 
variability. Within- beat coefficient of variation for Simpson’s biplane 
LVEF, GLS and E/e’ between 3 index- beats, compared with 3, 5 and 
10 consecutive beats with 95% CI. E/e’, mitral E wave max/average 
diastolic tissue Doppler velocity from the septal and lateral annulus; 
GLS, global longitudinal strain; LVEF, left ventricular ejection fraction.
 on M











4 Bunting KV, et al. Heart 2021;0:1–7. doi:10.1136/heartjnl-2020-318557
Heart failure and cardiomyopathies
568 ms and the mean RR2 was 570 ms, with a mean RR1 to RR2 
ratio of 1.09.
For E/e’, the index- beat approach had the smallest CV of 25% 
(95% CI 24 to 26) and strongest ICC of 0.96 (0.95 to 0.97), 
compared with 40% (37 to 41) and 0.81 (0.76 to 0.85) for the 
average of 3 beats, 41% (40 to 43) and 0.77 (0.72 to 0.81) for 
the average of 5 beats, and 41% (41 to 42) and 0.78 (0.73 to 
0.81) for the average of 10 beats. The mean RR1 of the index- 
beat was 653 ms and the mean RR2 was 655 ms, with a mean 
RR1 to RR2 ratio of 1.00.
Intraoperator and interoperator reproducibility
Intraoperator reproducibility of the index- beat method compared 
with consecutive beat averaging was assessed in 50 patients for 
E/e’ and GLS (with similar patient characteristics to the main 
cohort; online supplemental table 3). For E/e’, the index- beat 
had the smallest bias at −0.2 with similar limits of agreement 
to the average of 10 beats (−4.2 to 3.9) and the highest ICC of 
0.91 (95% CI 0.84 to 0.95) (table 4 and online supplemental 
figure 2). Similar findings were seen for GLS, with the index- 
beat method having the smallest bias at −0.5 with narrow limits 
of agreement (−3.6 to 2.6) and the highest ICC of 0.82 (95% 
CI 0.72 to 0.90) (online supplemental table 4 and online supple-
mental figure 2).
Interoperator reproducibility was tested in 18 randomly 
selected patients for GLS and E/e’, with a new set of images taken 
by a second operator (with similar patient characteristics as seen 
in online supplemental table 3). The index- beat demonstrated 
only a small degree of bias for both GLS and E/e’. ICC values 
for the index- beat were 0.72 for GLS (95% CI 0.45 to 0.88) 
and 0.94 for E/e’ (95% CI 0.87 to 0.98) (table 4, online supple-
mental table 4 and supplemental figure 3). Comparison of the 
second operator’s assessment of E/e’ with measurements taken 
by the first operator (from a different set of images) demon-
strated that the index- beat method had similar or higher levels of 
reproducibility than averaging 5 or 10 consecutive beats: Bland 
and Altman bias (limits of agreement) of −0.6 (−3.5 to 4.6), vs 
0.8 for 5 beats (−3.3 to 4.9) and 0.4 for 10 beats (−2.7 to 3.6).
Efficiency and validity of the index-beat method
The index- beat method took significantly less time to measure 
E/e’ (mean 35.4 s; 95% CI 33.1 to 37.8), compared with aver-
aging 5 consecutive beats (44.7 s; 41.8 to 47.5; p<0.001) or 
10 consecutive beats (98.1 s; 91.7 to 104.4; p<0.001) (figure 3 
and table 4). Using the index- beat method saved 9.3 and 62.7 s, 
respectively (absolute difference in means).
Despite only using a single index- beat, there was no evidence 
that this impacted on the validity; there were no significant 
differences in the correlation of NT- proBNP with echocardio-
graphic variables when comparing index- beats with conven-
tional averaging (figure 3). For example, the correlation of 
LVEF with NT- proBNP was 0.11 using a single index- beat 
Table 3 Within- beat variability of 3 index- beats versus 3, 5 and 10 consecutive beats

















3 index- beats 32 (31 to 34) 0.94 (0.93 to 0.96) 26 (25 to 27) 0.88 (0.85 to 0.91) 25 (24 to 26) 0.96 (0.95 to 0.97)
3 consecutive beats 54 (52 to 57) 0.71 (0.64 to 0.77) 44 (42 to 46) 0.81 (0.76 to 0.85) 40 (37 to 41) 0.81 (0.76 to 0.85)
5 consecutive beats 51 (50 to 53) 0.76 (0.71 to 0.81) 43 (42 to 44) 0.82 (0.77 to 0.85) 41 (40 to 43) 0.77 (0.72 to 0.81)
10 consecutive beats 53 (52 to 54) 0.74 (0.69 to 0.79) 42 (41 to 43) 0.80 (0.75 to 0.84) 41 (41 to 42) 0.78 (0.73 to 0.81)
E/e', mitral E wave max/average diastolic tissue Doppler velocity from the septal and lateral annulus; GLS, global longitudinal strain; LVEF, left ventricular ejection fraction.
Figure 3 Reproducibility, validity and time efficiency of the index- beat approach for E/e’. Comparison of the index- beat method verses averaging of 
5 and 10 consecutive beats for: (1) Reproducibility (ICC and 95% CI for within- beat, intra- and inter- operator variability); (2) Validity (beta coefficient 
for NT- proBNP with 95% CI); and (3) Time taken to measure E/e’ (mean seconds, with 95% CI). E/e’, mitral E wave max / average diastolic tissue 
Doppler velocity from the septal and lateral annulus; ICC, intraclass correlation coefficient; NT- proBNP, N- terminal pro- B- type natriuretic peptide.
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(p<0.001) vs 0.10 for 10 consecutive beats (p<0.001), with 
no significant difference between the two methods (p=0.84). 
Additional correlations for LVEF, GLS and E/e’ are presented in 
online supplemental table 5. Using the index- beat method led to 
reclassification of LVEF compared with 10- beat analysis (online 
supplemental table 6).
DISCUSSION
This study has demonstrated that the index- beat method 
produces more reproducible quantification of systolic and 
diastolic left ventricular function in patients with AF than 
conventional averaging of consecutive beats, while saving 
time and without compromising validity. The within- beat 
coefficient of variability and intraobserver/interobserver 
reproducibility were all favourable using the index- beat 
approach to imaging in patients who have a variable stroke 
volume and filling time. Using the index- beat method 
routinely in clinical practice has the potential to improve 
workflow and productivity, enhance the reliability of echo-
cardiography, and provide more confidence in the diagnosis 
and classification of heart failure in patients with AF.
Heart failure is common in patients with AF, and accurate 
assessment of systolic and diastolic left ventricular function is 
essential for patient management.4 Although current guidelines 
recommend averaging 5–10 consecutive beats,6 14 15 this is based 
on consensus opinion and lacks reliable evidence.16 Measuring 
consecutive beats is time- consuming and the overall measure-
ment obtained will vary according to which beats are selected, 
making reliability in clinical practice uncertain.17 18 AF is char-
acterised by a loss of atrial contraction and so ventricular filling 
relies heavily on the length of the R- R interval, with variation in 
intervals leading to considerable challenges to achieve reproduc-
ible measurements.19 In addition to cycle length, stroke volume 
is critically dependent on preload, and this is also variable in the 
setting of AF.9
It is important to note the very high levels of variation 
we demonstrate using the guideline- recommended 10 
consecutive- beat analysis; the CV of 41% for E/e’ should 
be considered unacceptable, highlighting the limitations of 
current practice in patients with AF. The influence of the 
R- R interval on contractility is believed to be caused by 
preload and uptake of calcium during the relaxation phase. 
The longer the R- R interval, the more time for calcium 
uptake and the greater the amount released in response to 
the sequential action potential, triggering a greater force of 
contraction.20 As ventricular filling and stroke volume for 
a particular beat are determined by the previous two R- R 
intervals, the index- beat method selects a cardiac cycle for 
analysis where the preceding and pre- preceding R- R interval 
are of similar duration. Hence, the real value of the index- 
beat method may be to achieve a more physiologically 
appropriate measurement. In this context, the end diastolic 
volume should be similar and so the contractility will also be 
similar, producing less variability between index- beats when 
assessing systolic function.19 21 22 The reliance on previous 
cycle lengths will also apply to GLS for detection of early 
myocardial dysfunction17 23 and diastolic filling indices such 
as E/e’.24 25
Intraoperator reproducibility for both GLS and E/e’ was 
shown to be highest when measuring on a single index- beat. 
Previous studies assessing strain rate have found a strong correla-
tion between the index- beat and averages of 10 and 15 beats 
with high levels of agreement.17 26 We also demonstrated that the 
index- beat method has a high level of reproducibility between 
different operators, an important contribution to value within 
the clinical setting, enhancing the practicality and usefulness of 
serial scans.
Strengths and limitations
A major concern with nearly all previous studies is the preselec-
tion of patients with ‘good echocardiography windows’.7 27 This 
is the first study to our knowledge in which the index- beat method 
has been interrogated in all patients with no pre- exclusions to 
image quality or heart rate, and all patients confirmed as being 
in AF at the time of echocardiography. The trial- based setting 
allowed us to ‘double- blind’ the imaging process; anonymised 
analyses were performed offline with a separate random code 
to the study identification number, and operators were blinded 
to patient details, clinical status and therapy. When compared 
with consecutive beats, our study showed no compromise in the 
correlation with NT- proBNP, a useful prognostic marker for both 
heart failure and coronary disease.28 However, this is clearly a 
limited analysis, and as the weak correlations between LVEF and 
NT- proBNP show, natriuretic peptide levels can be influenced 
by a variety of factors, including AF itself.29 When measured on 
an- index beat, LVEF was higher, on average, than using consec-
utive beats, and we also demonstrated that the index- beat led to 
reclassification of LVEF (online supplemental table 6). However, 
as we lack ‘ground truth’, further studies are warranted to 
compare the association of index- beat measurements with 
long- term clinical events in AF, and validation against invasive 
haemodynamic measurements. Our study was limited by non- 
simultaneous acquisition of Doppler and chamber images, and 
although this is currently standard practice globally there are 
single- beat options available for E/e’ that can also be valuable in 
AF.30 With pressure on echocardiography services increasing due 
to growing patient populations and wider indications, the index- 
beat method could increase the efficiency of echocardiography 
in AF; however, this was tested in a limited number of patients 
and only for E/e’. Qualitative assessment is also desirable to 
establish how to effectively introduce the index- beat approach 
in cardiology departments and the training required to aid clin-
ical productivity.
Table 4 Intraoperator and interoperator reproducibility and time efficiency for E/e’
Intraoperator reproducibility, n=50 Interoperator reproducibility, n=18 Time taken (s) to 
select and measure 
E/e’ (95% CI), n=18
Bias (limits of 
agreement) ICC (95% CI)
Bias (limits of 
agreement) ICC (95% CI)
Single index- beat −0.2 (−4.2 to 3.9) 0.91 (0.84 to 0.95) −0.3 (−2.9 to 2.2) 0.94 (0.87 to 0.98) 35.4 (33.1 to 37.8)
3 consecutive beats −0.7 (−6.2 to 4.8) 0.74 (0.60 to 0.85) −1.1 (−5.4 to 3.2) 0.83 (0.64 to 0.93) Not performed
5 consecutive beats −0.6 (−5.3 to 4.2) 0.80 (0.68 to 0.88) −1.1 (−6.5 to 4.2) 0.78 (0.56 to 0.91) 44.7 (41.8 to 47.5)
10 consecutive beats −0.4 (−4.2 to 3.4) 0.88 (0.80 to 0.93) −0.9 (−6.1 to 4.2) 0.82 (0.62 to 0.93) 98.1 (91.7 to 104.4)
E/e’, mitral E wave max/average diastolic tissue Doppler velocity from the septal and lateral annulus; ICC, intraclass correlation coefficient.
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CONCLUSION
In a blinded analysis without preselection for image quality, 
assessing left ventricular function using the index- beat method 
provides a more reproducible and quicker method of assessing 
heart function in patients with AF. Pending independent vali-
dation, our results suggest that echocardiography departments 
should change to the index- beat method to diagnose and charac-
terise heart failure in patients with AF.
Key messages
What is already known on this subject?
 ► Accurate assessment of ventricular function is essential to 
diagnose the type of heart failure in patients with atrial 
fibrillation (AF) and guide treatment strategies.
 ► However, measuring ventricular function in patients with AF 
is challenging due to the irregular cardiac cycle length.
What might this study add?
 ► The index- beat approach, whereby measurements of 
ventricular function are taken after two cycles with a similar 
R- R interval, was compared with conventional averaging of 
consecutive beats.
 ► We demonstrated that the index- beat approach was more 
reproducible, more time- efficient and did not compromise 
clinical validity against natriuretic peptide levels.
How might this impact on clinical practice?
 ► Pending external validation, use of the index- beat in clinical 
practice could improve the assessment of ventricular function, 
leading to more precise treatment strategies for patients with 
AF and the potential for fewer hospital admissions and better 
patient quality of life.
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